Overview
Dr. Andrew Nixon is Professor of Medicine in the Department of Medicine/Division of Medical Oncology at Duke University. He holds a BS in chemistry from Miami University, a PhD in biochemistry from Wake Forest University, and an MBA with a focus on healthcare management from Duke University/Fuqua School of Business. He is a nationally recognized expert in the development of cancer biomarkers and correlative science, with extensive experience leading large multi-center biomarker analyses. Dr. Nixon serves in various leadership roles within the National Cancer Institute (NCI), working with diverse multi-disciplinary teams focused on improving cancer patient outcomes through biomarker science. He serves as the national co-chair for the NCI Core Correlative Sciences Committee which adjudicates the use of biospecimens collected throughout the NCI National Clinical Trial Network (NCTN). Within the NCI-NCTN Alliance cooperative group, Dr. Nixon has multiple leadership positions including serving on the Alliance Board of Directors, co-chair of the Immuno-Oncology Committee, co-chair for Gastrointestinal Correlative Research, and has been an executive member of the Translational Research Program since its inception. Additionally, within the NCI-NCTN NRG cooperative group, he serves as a member of the Gynecologic Translational Science Committee and on the Gynecological Oncology Group - Partners Investigator Council Translational Research Subcommittee. Dr. Nixon is an American Society for Clinical Oncology (ASCO) Ambassador and has chaired various committees and led scientific and educational sessions at national conferences. Recently, Dr. Nixon has focused his research on cellular senescence and biomarkers of aging and early carcinogenesis. He serves as Principal Investigator for a large multi-center NIH grant to develop high-resolution tissue maps and biomarkers of cellular senescence as a part of the Senescence Network (SenNet) Consortium.
Current Appointments & Affiliations
Recent Publications
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).
Journal Article Clin Cancer Res · March 17, 2025 PURPOSE: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody-drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assessed the safety, ac ... Full text Link to item CiteCharacterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants.
Journal Article Cancer Epidemiol Biomarkers Prev · January 9, 2025 BACKGROUND: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here ... Full text Link to item CiteSupplementary Table S5 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Other · January 9, 2025 <p>Supplementary Table S5 shows three potential measures of variance.</p> ... Full text CiteRecent Grants
Targeting Hepatocyte Senescence to Improve NAFLD
ResearchAdvisor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029Targeting Hepatocyte Senescence to Improve NAFLD
ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2029Drug Development for Dystonia
ResearchCo Investigator · Awarded by Department of Defense · 2023 - 2027View All Grants